- Home
- NLSP vs TXMD Comparison
NLSP vs TXMD Comparison
Compare NLSP & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- TXMD
- Stock Information
- Founded
- NLSP 2015
- TXMD 2008
- Country
- NLSP Switzerland
- TXMD United States
- Employees
- NLSP N/A
- TXMD N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- TXMD Health Care
- Exchange
- NLSP Nasdaq
- TXMD Nasdaq
- Market Cap
- NLSP 12.4M
- TXMD 12.3M
- IPO Year
- NLSP 2021
- TXMD N/A
- Fundamental
- Price
- NLSP $1.63
- TXMD $1.05
- Analyst Decision
- NLSP
- TXMD
- Analyst Count
- NLSP 0
- TXMD 0
- Target Price
- NLSP N/A
- TXMD N/A
- AVG Volume (30 Days)
- NLSP 896.7K
- TXMD 17.3K
- Earning Date
- NLSP 10-06-2025
- TXMD 11-11-2025
- Dividend Yield
- NLSP N/A
- TXMD N/A
- EPS Growth
- NLSP N/A
- TXMD N/A
- EPS
- NLSP N/A
- TXMD N/A
- Revenue
- NLSP N/A
- TXMD $2,559,000.00
- Revenue This Year
- NLSP N/A
- TXMD $427.09
- Revenue Next Year
- NLSP N/A
- TXMD N/A
- P/E Ratio
- NLSP N/A
- TXMD N/A
- Revenue Growth
- NLSP N/A
- TXMD 156.93
- 52 Week Low
- NLSP $1.30
- TXMD $0.70
- 52 Week High
- NLSP $5.64
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- NLSP 36.11
- TXMD 42.68
- Support Level
- NLSP $1.45
- TXMD $0.99
- Resistance Level
- NLSP $1.89
- TXMD $1.09
- Average True Range (ATR)
- NLSP 0.18
- TXMD 0.03
- MACD
- NLSP -0.03
- TXMD -0.00
- Stochastic Oscillator
- NLSP 17.82
- TXMD 45.45
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.